Robert Hershberg Biography and Net Worth

Director of Recursion Pharmaceuticals

Robert Hershberg, M.D., Ph.D., has served as a member of our Board since March 2020. He has served as a Venture Partner at Frazier Healthcare Partners since March 2020. Previously, Dr. Hershberg served as the President, Chief Executive Officer and Chairman of the Board of Directors of HilleVax, Inc, from March 2020 to September 2025. Previously, from April 2017 to March 2020, Dr. Hershberg was the executive vice president and head of business development and global alliances at Celgene (acquired by Bristol-Myers Squibb in 2019). He was employed in positions of ascending responsibility at Celgene since joining the company in 2014, including his role as Chief Scientific Officer from January 2016 to March 2020. Before Celgene, he served several roles at VentiRx Pharmaceuticals, a clinical-stage biopharmaceutical company which he co-founded in 2006 and was Chief Executive Officer from September 2012 until the company’s acquisition by Celgene in February 2017. Dr. Hershberg currently serves on the board of directors of Adaptive Biotechnology and AtaiBeckley. He previously served on the boards of directors of Nanostring Technologies, Inc., from 2015 to April 2022, Silverback Therapeutics, from 2017 to November 2022, and Fate Therapeutics, from 2020 to June 2024. He also serves on the scientific advisory board of Danaher. He holds a Ph.D. in biology from the University of California, San Diego’s Affiliated Ph.D. program with the Salk Institute and an M.D. and a B.A. from the University of California, Los Angeles, completed under the Medical Scientist Training Program (MSTP).

What is Robert Hershberg's net worth?: The estimated net worth of Robert Hershberg is at least $692.41 thousand as of October 6th, 2026. Dr. Hershberg owns 162,156 shares of Recursion Pharmaceuticals stock worth more than $692,406 as of October 8th. This net worth approximation does not reflect any other investments that Dr. Hershberg may own. Learn More about Robert Hershberg's net worth.
How do I contact Robert Hershberg?: The corporate mailing address for Dr. Hershberg and other Recursion Pharmaceuticals executives is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. Recursion Pharmaceuticals can also be reached via phone at 385-269-0203 and via email at [email protected]. Learn More on Robert Hershberg's contact information.
Has Robert Hershberg been buying or selling shares of Recursion Pharmaceuticals?: During the last ninety days, Robert Hershberg has sold $125,000.00 of Recursion Pharmaceuticals stock. Most recently, Robert Hershberg sold 25,000 shares of the business's stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $5.00, for a transaction totalling $125,000.00. Following the completion of the sale, the director now directly owns 162,156 shares of the company's stock, valued at $810,780. Learn More on Robert Hershberg's trading history.
Who are Recursion Pharmaceuticals' active insiders?: Recursion Pharmaceuticals' insider roster includes Blake Borgeson (Director), Namandje Bumpus (Director), Terry-Ann Burrell (Director), Zavain Dar (Director), Christopher Gibson (CEO), Robert Hershberg (Director), Najat Khan (Insider), Tina Larson (COO), Dean Li (Director), Tina Marriott (President & COO), Michael Secora (CFO), Ben Taylor (CFO), and Shafique Virani (Chief Corporate Development Officer). Learn More on Recursion Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Recursion Pharmaceuticals?: In the last year, insiders at the sold shares 20 times. They sold a total of 1,174,811 shares worth more than $4,869,269.37. The most recent insider tranaction occured on October, 6th when Director Blake Borgeson sold 50,000 shares worth more than $242,000.00. Insiders at Recursion Pharmaceuticals own 6.7% of the company. Learn More about insider trades at Recursion Pharmaceuticals.
Information on this page was last updated on 10/6/2026.

Robert Hershberg Insider Trading History at Recursion Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/6/2026	Sell	25,000	$5.00	$125,000.00	162,156

Robert Hershberg Buying and Selling Activity at Recursion Pharmaceuticals

Recursion Pharmaceuticals Company Overview

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $4.27

$4.23

$4.60

50 Day Range

MA: $3.52

$3.00

$4.78

2 Week Range

Now: $4.27

$2.77

$7.18

Volume

40,600,630 shs

Average Volume

26,151,508 shs

Market Capitalization

$2.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04